Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Ovid Therapeutics (NASDAQ:OVID) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
1
1
0
0
Last 30D
0
0
1
0
0
1M Ago
2
0
0
0
0
2M Ago
0
1
0
0
0
3M Ago
0
0
0
0
0
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $7.38, along with a high estimate of $9.00 and a low estimate of $3.50. This upward trend is evident, with the current average reflecting a 84.5% increase from the previous average price target of $4.00.
Breaking Down Analyst Ratings: A Detailed Examination
In examining recent analyst actions, we gain insights into how financial experts perceive Ovid Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Yigal Nochomovitz
Citigroup
Lowers
Neutral
$3.50
$4.00
Kalpit Patel
B. Riley Securities
Announces
Buy
$9.00
-
Raghuram Selvaraju
HC Wainwright & Co.
Announces
Buy
$9.00
-
Laura Chico
Wedbush
Announces
Outperform
$8.00
-
Key Insights:
Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ovid Therapeutics. ...Full story available on Benzinga.com
Benzinga